Alaska Permanent Fund Corp Biomarin Pharmaceutical Inc Transaction History

Alaska Permanent Fund Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$80.93 - $108.63 $10,035 - $13,470	-124 Reduced 33.79%	243 $25,000
Q3 2022 Oct 31, 2022	SELL	$82.16 - $96.94 $903 - $1,066	-11 Reduced 2.91%	367 $31,000
Q2 2022 Aug 09, 2022	SELL	$71.48 - $86.85 $14,653 - $17,804	-205 Reduced 35.16%	378 $32,000
Q1 2022 Apr 26, 2022	SELL	$74.28 - $92.69 $5,645 - $7,044	-76 Reduced 11.53%	583 $45,000
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $47,263 - $60,278	659 New	659 $58,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Alaska Permanent Fund Corp, based on Form 13F filings with the SEC.

Stay updated on Alaska Permanent Fund Corp with notifications on news.